Edap Tms (EDAP) Expected to Announce Earnings on Wednesday

Edap Tms (NASDAQ:EDAP) is projected to post its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Edap Tms to post earnings of ($0.16) per share and revenue of $21.28 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 8:30 AM ET.

Edap Tms Price Performance

Edap Tms stock opened at $3.91 on Wednesday. The company has a market capitalization of $146.19 million, a price-to-earnings ratio of -6.86 and a beta of -0.19. The company has a current ratio of 1.41, a quick ratio of 0.97 and a debt-to-equity ratio of 0.04. Edap Tms has a 12 month low of $1.21 and a 12 month high of $5.05. The stock’s 50 day moving average is $4.23 and its 200-day moving average is $3.14.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Edap Tms stock. Kovack Advisors Inc. acquired a new position in shares of Edap Tms S.A. (NASDAQ:EDAP) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,000 shares of the medical equipment provider’s stock, valued at approximately $53,000. 62.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on EDAP. Weiss Ratings restated a “sell (d-)” rating on shares of Edap Tms in a research note on Monday, December 29th. Wall Street Zen upgraded Edap Tms to a “hold” rating in a research report on Saturday, February 7th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Edap Tms currently has a consensus rating of “Hold” and an average target price of $8.50.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.